(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.
Citius Pharmaceuticals's earnings in 2025 is -$40,990,540.On average, 1 Wall Street analyst forecast CTXR's earnings for 2025 to be -$68,729,252, with the lowest CTXR earnings forecast at -$68,729,252, and the highest CTXR earnings forecast at -$68,729,252.
In 2026, CTXR is forecast to generate -$3,402,438 in earnings, with the lowest earnings forecast at -$3,402,438 and the highest earnings forecast at -$3,402,438.